(MedPage Today) — An implantable, drug-eluting microdevice showed promise for informing decisions about systemic therapy for prostate cancer prior to radical prostatectomy for high-risk disease, according to results of a pilot study.
Percutaneously…
Source link : https://www.medpagetoday.com/hematologyoncology/prostatecancer/114097
Author :
Publish date : 2025-02-05 21:09:44
Copyright for syndicated content belongs to the linked Source.
